Short Lecture "method Development for Pilot Production of Astragaloside Vii"

Abstract

Based on the promising immunostimulant effect comparable to commercialized adjuvants Alum and Quillaja saponins (including QS-21) [1], [2], [3], our team has been prompted to carry out advance studies for developing Astragaloside VII (AST VII) ([Fig. 1]) as a new vaccine adjuvant or an immunotherapeutic agent. Hence, one of the most critical challenges is establishing efficient isolation and purification processes to obtain AST VII on a large scale. Thus, this study aimed to develop a production methodology for AST VII from Turkish Astragalus species.